MarketPeel
Insider Trading Intelligence
Pricing
…
DC

David D. Chang

ALLO
PRESIDENT AND CEO · ALLOGENE THERAPEUTICS, INC. · CIK 0001611024
FILING MIX · LIFETIME65%/35%
BUYS
20
SELLS
11
TOTAL VALUE
$3.68M
COMPANIES
1
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
5,150,599
AVG SELL PX
$5.79
TRADE KIND
SHOWING 31 / 31
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
8 backtested trades · 8 horizons · 8 pending
Forward-return performance of every backtestable P/S trade by David D. Chang, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d8+50.00%-0.74%-1.05%+0.30%-0.15%—
14d8+37.50%+11.05%+2.78%+8.26%-0.49%—
30d8+37.50%+10.13%+4.62%+5.51%+10.38%—
60d8+62.50%+27.41%+4.34%+23.07%-0.21%—
90d8+50.00%+25.44%+8.71%+16.72%+10.03%—
180d8(2 pending)+50.00%+20.59%+18.71%+1.88%-2.10%—
1y8(2 pending)+33.33%+22.63%+28.64%-6.00%-2.91%—
2y8(4 pending)+100.00%-59.14%+50.20%-109.34%-114.24%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ALLO · 5,150,599 shares · as of Mar 16, 2026
01,340,8102,681,6204,022,4305,363,240202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 20 buys / 11 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
47,763$2.47$118.0K5,150,599Mar 16, 2026Mar 18, 2026 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
392,586——392,586Feb 2, 2026Feb 4, 2026 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,387,931——1,387,931Feb 2, 2026Feb 4, 2026 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
95,269$1.80$171.5K5,185,862Feb 2, 2026Feb 4, 2026 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
46,668$1.96$91.5K5,276,569Mar 14, 2025Mar 18, 2025 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
46,003$1.68$77.3K5,317,237Feb 3, 2025Feb 5, 2025 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
552,174——5,363,240Jan 24, 2025Jan 28, 2025 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,952,130——1,952,130Jan 24, 2025Jan 28, 2025 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
344,828$2.90$1.00M4,810,106May 16, 2024May 20, 2024 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
53,393$4.33$231.2K4,465,278Mar 14, 2024Mar 18, 2024 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
317,800——4,513,203Jan 25, 2024Jan 31, 2024 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,123,535——1,123,535Jan 25, 2024Jan 31, 2024 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,924,464——4,193,911Mar 22, 2023Mar 24, 2023 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,492,200——1,492,200Mar 22, 2023Mar 24, 2023 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
22,340$5.56$124.2K2,269,447Mar 14, 2023Mar 16, 2023 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,195,512——2,195,512Mar 23, 2022Mar 25, 2022 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
23,648$7.65$180.9K2,289,652Mar 15, 2022Mar 17, 2022 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
President and CEO
27,410$18.22$499.4K2,312,279May 24, 2021May 24, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
27,410——541,190May 24, 2021May 24, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
80,452——2,284,869Mar 26, 2021Mar 30, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
298,836——298,836Mar 26, 2021Mar 30, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
20,513$38.57$791.3K2,204,417Mar 15, 2021Mar 17, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Gift
205,778——856,044Aug 31, 2020Apr 2, 2021 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
President and CEO
9,198——1,201,108Apr 24, 2020Apr 28, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
President and CEO
9,187——2,224,101Apr 24, 2020Apr 28, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
568,600——568,600Mar 18, 2020Mar 20, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Gift
428,022——650,266Mar 18, 2020Apr 28, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
18,710$19.24$360.0K2,215,426Mar 16, 2020Mar 18, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
President and CEO
1,625$20.06$32.6K2,214,914Mar 16, 2020Mar 18, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
President and CEO
9,391——2,234,136Mar 4, 2020Mar 11, 2020 ↗View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASE
President and CEO
9,402——1,191,910Mar 4, 2020Mar 11, 2020 ↗View →
Other insiders · ALLO
Loading peer insiders…
About this filer
CIK 0001611024
ROLE
President and CEO
PRIMARY
ALLO
COMPANIES
1
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001611024DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback